Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Reply to: “Regarding ‘PET/CT Imaging Characteristics After Radioembolization of Hepatic Metastasis from Breast Cancer’”

We read the commenter’s letter with interest. We acknowledge that the terminology in our text could have been clearer—our use of the term “dose,” based on historical use of the term, to describe amounts of activity should be updated in modern literature. We thank the commenter for their diligence.

Without intending to lessen the correctness of the commenter’s objection, the topic of dose (both administered activity and absorbed dose) was tertiary to our work and its conclusions. We aimed to review impact of vendor-recommended radioembolization protocols using PERCIST criteria. Absorbed dose and response relationships were not studied at any depth. Figure 3 was shown because administration activity and absorbed dose calculation methodologies vary significantly across the field and across the vendor products included in our study [1], whereas the ultimate administered activity (in units of mCi) can be stated concisely and without compounding assumptions. The correlation of dose with radioembolization response assessment should be further studied in future work.

Reference

  1. 1.

    Dezarn WA, Cessna JT, DeWerd LA, et al. Recommendations of the American Association of Physicists in Medicine on dosimetry, imaging, and quality assurance procedures for 90Y microsphere brachytherapy in the treatment of hepatic malignancies. Med Phys. 2011;38:4824–45.

Download references

Funding

This research was partly funded through the NIH/NCI Cancer Center Support Grant P30 CA008748 and the Breast Cancer Research Foundation.

Author information

Correspondence to Amy R. Deipolyi.

Ethics declarations

Conflict of interest

Dr. Deipolyi reports personal fees from BTG, Inc., and personal fees from Dova Pharmaceuticals, outside the submitted work. Dr. Boas is a co-founder of Claripacs, LLC, and received a research grant and supplies from Guerbet, research support from GE, research supplies from Bayer, and a research grant and speaker fees from Society of Interventional Oncology, sponsored by Guerbet; he is also an investor in Labdoor, Qventus, CloudMedx, Notable Labs, and Xgenomes. Dr. Yarmohammadi received research grants from the Thompson Foundation and Guerbet. Dr. Sofocleous received consulting fees from Terumo and consulting fees and research funding from BTG and Johnson and Johnson. The other authors have no disclosures.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Deipolyi, A.R., England, R.W., Ridouani, F. et al. Reply to: “Regarding ‘PET/CT Imaging Characteristics After Radioembolization of Hepatic Metastasis from Breast Cancer’”. Cardiovasc Intervent Radiol (2020). https://doi.org/10.1007/s00270-020-02428-2

Download citation